Defense stocks surged amid the escalating conflict in the Middle East while military budgets continue to expand. Click here ...
Bill Cooper stated, "We expect a sequential decline in non-product revenue due to a project completion in Q4 2025, which will ...
MicroVision, Inc. (NASDAQ:MVIS) Q4 2025 Earnings Call Transcript March 5, 2026 Operator: Good afternoon, and welcome to the MicroVision Fourth Quarter and Full Year 2025 Financial and Operating ...
Pediatric Rheumatologist Explains Many New Updates to ACR’s Juvenile Idiopathic Arthritis Guidelines
The new draft guidelines favor earlier DMARD therapy with ‘much decreased reliance on glucocorticoids that have several side ...
In the latest edition of our 'In Conversation With...' series, H.B. Fuller walks us through its rebranded coatings portfolio and expanded innovation focus - and how its solutions could help customers ...
Stratasys Ltd. (NASDAQ:SSYS) Q4 2025 Earnings Call Transcript March 5, 2026 Stratasys Ltd. beats earnings expectations. Reported EPS is $0.07, expectations were $0.05. Operator: Good day, and welcome ...
Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On track for expanded pancreatic cancer ...
Welcome to Endeavour Mining's Fourth Quarter and Full Year 2025 Results Webcast. [Operator Instructions] Today's conference call is being recorded, and a transcript of the call will be available on ...
The HR 64Mb xSPI STT-MRAM has now completed full production qualification for the AEC-Q100 Grade 1 specification. It is currently available for customer orders and supports high-volume production ...
When Chadrack Mpoyi arrived from Congo, the Crean Lutheran basketball community helped him adapt to amid grief and earn a ...
At MWC 2026, Lenovo builds on the momentum from CES and Tech World to highlight its latest portfolio of AI-powered business devices, intelligent form factors, and enterprise-ready platforms, designed ...
4d
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results